Blood test for VEGF-A, TGF-B1 prior to treatment could help determine tailored treatment options for oesophageal cancer patients

Results of a nine-year study of patients undergoing concurrent chemotherapy and radiotherapy (CCRT) for esophageal cancer show that levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response and disease-free survival rates, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.

Market Wired